



Freedom of Information Request: Our Reference CTMUHB_383_25

You asked:

I am conducting analysis on drugs used to treat inflammatory diseases and kindly request your help.

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) for the three-month period specified within the question.

I have provided a grid of drug names and department names requested (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Q1- How many patients were treated with the following drugs from the following departments (for any disease) from the start of April 2025 to the end of June 2025?

Please use the latest available 3 months if April to June is not available and specify which 3 months have been used.

Please find below a table providing information that Medicines Management are able to provide at this current time. The period the data relates to 1st April 2025 to 30th June 2025 as requested.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab	62	249	505
Apremilast	15		**
Bimekizumab	17		36
Brodalumab	**		
Certolizumab Pegol	5	**	73
Deucravacitinib	18		
Etanercept			291
Etrasimod			
Filgotinib		**	11
Golimumab			59
Guselkumab	55		**
Infliximab (Biosimilars)		261	22
Infliximab (Remicade)		**	
Ixekizumab	21		24
Mirikizumab			
Ozanimod			
Risankizumab	63	32	
Secukinumab	10		95

Tildrakizumab	14		
Tofacitinib		**	8
Upadacitinib	13	37	39
Ustekinumab	43	175	16
Vedolizumab		221	

Please note - Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.